Rivaroxaban given at doses of both 20mg and 15mg may have an improved bleeding risk profile compared with vitamin K antagponist.
Recommended dosing conversions for anticoagulants such as warfarin, heparin, and dabigatran.
American College of Cardiology 2011
Rivaroxaban is non-inferior to enoxaparin in short-term use and superior in long-term use for the prevention of venous thromboembolism (VTE) in acutely ill medical patients, but demonstrates weaker safety outcomes, according to results of the MAGELLAN trial presented today at ACC.11, the American College of Cardiology's 60th Annual Scientific Session.
Drugs in the Pipeline
Johnson & Johnson Pharmaceutical Research & Development announced results from its Phase 3 study of rivaroxaban in non-valvular atrial fibrillation (AF) patients to reduce the risk of stroke and non-CNS systemic embolism.
Authors find rivaroxaban not noninferior to vitamin K antagonists for secondary thromboprophylaxis.
Data from large Phase 3 studies showed that treatment with rivaroxaban was found to be safe and effective in older patients.
Primary end point occurred in lower percentage of patients in 180-day period; difference not significant
An alternative approach to treating potentially fatal blood clots may be more effective, cheaper, and may allow patients to go home the same day, researchers from the Indiana University School of Medicine reported.
American College of Cardiology 2013
At ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, Anil Rajendra, MD, from the Medical University of South Carolina, in Charleston, SC, presented data showing similar bleeding and thrombotic complication rates at the time of atrial fibrillation ablation (AFA) in patients anticoagulated with dabigatran and rivaroxaban. Dr. Rajendra and colleagues determined that rivaroxaban has an acceptable safety profile for AFA.